Literature DB >> 16045572

Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial.

H Bergquist1, U Wenger, E Johnsson, J Nyman, H Ejnell, E Hammerlid, L Lundell, M Ruth.   

Abstract

SUMMARY: Esophageal cancer often presents as advanced stage disease with a dismal prognosis, with only 10-15% of patients surviving 5 years. Therefore, in a large proportion of patients, palliative treatment is the only option available. The aim of this study was to prospectively compare the palliative effect of self-expandable stent placement with that of endoluminal brachytherapy regarding the effect on quality of life and on specific symptoms. Sixty-five patients with advanced cancer of the esophagus or gastroesophageal junction were randomized to treatment with either an Ultraflex expandable stent or high-dose-rate endoluminal brachytherapy with 7 Gy x 3 given in 2-4 weeks. Clinical assessment and health-related quality of life (HRQL) were measured at inclusion and 1, 3, 6, 9 and 12 months later. The HRQL was measured with standardized questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Oesophageal Module and Hospital Anxiety and Depression Scale). Twenty-eight patients completed the stent treatment and 24 patients the brachytherapy. The group of patients treated with stent reported significantly better HRQL scores for dysphagia (P < 0.05) at the 1-month follow-up, but most other HRQL scores, including functioning and symptom scales, deteriorated. Among brachytherapy-treated patients, improvement was found for the dysphagia-related scores at the 3-months follow-up, whereas other significant changes of scores were few. The median survival time was comparable in the two groups (around 120 days). In conclusion, insertion of self-expandable metal stents offered a more instant relief of dysphagia compared to endoluminal brachytherapy, but HRQL was more stable in the brachytherapy group.

Entities:  

Mesh:

Year:  2005        PMID: 16045572     DOI: 10.1111/j.1442-2050.2005.00467.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  37 in total

1.  Recommendations of the Spanish Brachytherapy Group of SEOR for HDR endoluminal treatments. Part 1: Oesophagus.

Authors:  Á Rovirosa; J Anchuelo; V Crispin; C Gutiérrez; A Herreros; I Herruzo; J C Menéndez; P Pino; A Polo; S Rodríguez
Journal:  Clin Transl Oncol       Date:  2015-04-17       Impact factor: 3.405

2.  The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes.

Authors:  George Sgourakis; Ines Gockel; Arnold Radtke; Georgia Dedemadi; Konstantinos Goumas; Sofia Mylona; Hauke Lang; Achilleas Tsiamis; Constantine Karaliotas
Journal:  Dig Dis Sci       Date:  2010-05-04       Impact factor: 3.199

3.  High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer : Experience from a large single-center cohort.

Authors:  Nils H Nicolay; Johanna Rademacher; Jan Oelmann-Avendano; Jürgen Debus; Peter E Huber; Katja Lindel
Journal:  Strahlenther Onkol       Date:  2016-05-31       Impact factor: 3.621

Review 4.  Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends.

Authors:  Peter S N van Rossum; Nadia Haj Mohammad; Frank P Vleggaar; Richard van Hillegersberg
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-12-13       Impact factor: 46.802

Review 5.  Oesophageal cancer--an overview.

Authors:  Michael Schweigert; Attila Dubecz; Hubert J Stein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

6.  Safety and efficacy of esophageal stents preceding or during neoadjuvant chemotherapy for esophageal cancer: a systematic review and meta-analysis.

Authors:  Vinayak Nagaraja; Michael R Cox; Guy D Eslick
Journal:  J Gastrointest Oncol       Date:  2014-04

7.  Evolving Management of Zenker's Diverticulum in the Endoscopic Era: A North American Experience.

Authors:  Daniel Jones; Abdullah Aloraini; Stephen Gowing; Jonathan Cools-Lartigue; Mara Leimanis; Roger Tabah; Lorenzo Ferri
Journal:  World J Surg       Date:  2016-06       Impact factor: 3.352

8.  Cost-effectiveness of palliation of unresectable esophageal cancer.

Authors:  Eduardo B da Silveira; Everson L Artifon
Journal:  Dig Dis Sci       Date:  2008-06-04       Impact factor: 3.199

9.  Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.

Authors:  Andreas Fountoulakis; John Souglakos; Louiza Vini; Gerasimos N Douridas; Anna Koumarianou; Panteleimon Kountourakis; Christos Agalianos; Andreas Alexandrou; Christos Dervenis; Sofia Gourtsoyianni; Nikolaos Gouvas; Maria-Angeliki Kalogeridi; Georgia Levidou; Theodoros Liakakos; Joseph Sgouros; Spiros N Sgouros; Charikleia Triantopoulou; Evangelos Xynos
Journal:  Updates Surg       Date:  2019-12-02

10.  A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma.

Authors:  Ali Al-Fakeeh; Lorenzo Ferri; Nasser Mulla; Tonia Doerksen; Ibrahim Al-Ruzug; Fabiano Santos; Thierry Alcindor
Journal:  Med Oncol       Date:  2016-05-26       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.